Included in S&P Global Sustainability Yearbook (China Edition) 2026
2026-04-14

Included in S&P Global Sustainability Yearbook (China Edition) 2026

New Drug for Renal Anaemia Desidustat Tablets Approved in China
2026-03-13

New Drug for Renal Anaemia Desidustat Tablets Approved in China

Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
2026-03-12

Ruxolitinib Phosphate Cream (Lumirix®) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo

Self-Developed Innovative Drug INHBE-Targeting Small Nucleic Acid Drug CMS-D008 received IND approval for Overweight/Obesity Indication
2026-03-04

Self-Developed Innovative Drug INHBE-Targeting Small Nucleic Acid Drug CMS-D008 received IND approval for Overweight/Obesity Indication

Included in S&P Global Sustainability Yearbook 2026
2026-02-25

Included in S&P Global Sustainability Yearbook 2026

NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
2026-02-24

NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

Signed An Exclusive Distribution Agreement for the Original Drug Lidoderm® Lidocaine Cataplasms
2026-02-12

Signed An Exclusive Distribution Agreement for the Original Drug Lidoderm® Lidocaine Cataplasms

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Complement – mediated Kidney Disease Indication
2026-02-03

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Complement – mediated Kidney Disease Indication

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria Indication
2026-01-30

Self-developed Innovative Drug Complement Factor B Inhibitor CMS-D017 is approved for Drug Clinical Trials for Paroxysmal Nocturnal Hemoglobinuria Indication

Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

CMS Successively Awarded “Most Investment Value Award” and “Top 100 Hong Kong Listed Companies-Annual Pharmaceutical and Healthcare Innovation Pioneer”
2026-01-09

CMS Successively Awarded “Most Investment Value Award” and “Top 100 Hong Kong Listed Companies-Annual Pharmaceutical and Healthcare Innovation Pioneer”